Loxo Oncology reports positive results from Phase I study of larotrectinib to treat TRK fusion cancers

US-based biopharmaceutical company Loxo Oncology has reported positive results from its Phase I study of larotrectinib (LOXO-101) to treat tropomyosin receptor kinase (TRK) fusion cancers.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news